Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_assertion type Assertion NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_head.
- NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_provenance.
- NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_assertion evidence source_evidence_literature NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_provenance.
- NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_assertion SIO_000772 19293179 NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_provenance.
- NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_assertion wasDerivedFrom befree-2016 NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_provenance.
- NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_assertion wasGeneratedBy ECO_0000203 NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_provenance.